Daniel Schmitt is President and Chief Executive Officer of Actuate Therapeutics, Inc. (ACTU). The company reported total compensation of $2,166,522 for fiscal year 2025.
| Salary | $570,000 |
|---|---|
| Bonus | $142,329 |
| Stock awards | $0 |
| Option awards | $1,454,193 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $0 |
| Total | $2,166,522 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Actuate Therapeutics, Inc. filed April 6, 2026, accession 0001683168-26-002691.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $570,000 | $142,329 | $0 | $1,454,193 | $0 | $0 | $0 | $2,166,522 |
| FY2024 | President and Chief Executive Officer | $400,000 | $200,000 | $4,978,616 | $0 | $0 | $0 | $0 | $5,578,616 |
Totals as disclosed in each year's own compensation disclosure for Actuate Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel Schmitt this page | President and Chief Executive Officer | $2,166,522 |
| Andrew Mazar | Chief Operating Officer | $1,419,569 |
| Paul Lytle | Chief Financial Officer | $1,006,361 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Actuate Therapeutics, Inc. compensation brief.
Daniel Schmitt's compensation sits inside Actuate Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.